HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $0.5 Price Target

Outlook Therapeutics, Inc. -3.02%

Outlook Therapeutics, Inc.

OTLK

0.42

-3.02%

HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ: OTLK) with a Neutral and maintains $0.5 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via